Fresenius SE Income After Taxes 2016-2024 | FSNUY

Fresenius SE annual/quarterly income after taxes history and growth rate from 2016 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
  • Fresenius SE income after taxes for the quarter ending June 30, 2024 was $-0.013B, a 107.14% decline year-over-year.
  • Fresenius SE income after taxes for the twelve months ending June 30, 2024 was $-0.120B, a 107.31% decline year-over-year.
  • Fresenius SE annual income after taxes for 2023 was $0.258B, a 88.45% decline from 2022.
  • Fresenius SE annual income after taxes for 2022 was $2.23B, a 33.12% decline from 2021.
  • Fresenius SE annual income after taxes for 2021 was $3.335B, a 3.42% increase from 2020.
Fresenius SE Annual Income After Taxes
(Millions of US $)
2023 $258
2022 $2,230
2021 $3,335
2020 $3,225
2019 $3,392
2018 $4,386
2017 $3,428
2016 $2,981
2015 $2,551
Fresenius SE Quarterly Income After Taxes
(Millions of US $)
2024-06-30 $-13
2024-03-31 $314
2023-12-31 $-589
2023-09-30 $169
2023-06-30 $181
2023-03-31 $497
2022-12-31 $403
2022-09-30 $555
2022-06-30 $600
2022-03-31 $672
2021-12-31 $870
2021-09-30 $803
2021-06-30 $853
2021-03-31 $809
2020-12-31 $739
2020-09-30 $874
2020-06-30 $806
2020-03-31 $805
2019-12-31 $926
2019-09-30 $840
2019-06-30 $816
2019-03-31 $811
2018-12-31 $1,027
2018-09-30 $813
2018-06-30 $1,689
2018-03-31 $858
2017-12-31 $1,030
2017-09-30 $809
2017-06-30 $790
2017-03-31 $800
2016-12-31 $851
2016-09-30 $758
2016-06-30 $734
2016-03-31 $638
2015-12-31 $7,951
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $20.039B $24.011B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $17.877B 18.12
DaVita (DVA) United States $12.667B 16.38
Encompass Health (EHC) United States $10.405B 24.53
Chemed (CHE) United States $8.459B 26.00
Elanco Animal Health (ELAN) United States $7.054B 16.79
RadNet (RDNT) United States $6.388B 141.61
Option Care Health (OPCH) United States $3.890B 18.43
Amedisys (AMED) United States $3.035B 21.60
LifeStance Health (LFST) United States $2.828B 0.00
Addus HomeCare (ADUS) United States $2.320B 27.22
Astrana Health (ASTH) United States $2.297B 36.01
U.S Physical Therapy (USPH) United States $1.428B 37.54
Pennant (PNTG) United States $1.162B 46.99
Aveanna Healthcare Holdings (AVAH) United States $1.149B 0.00
Atai Life Sciences (ATAI) Germany $0.265B 0.00
Daxor (DXR) United States $0.042B 0.00
Psychemedics (PMD) United States $0.014B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.011B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00